Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05756764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-obesity Pharmacotherapy and Inflammation

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 9, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2025 to Jan 30, 2026
    • Study completion date: Jul 15, 2025 to Feb 20, 2026
    v8
  2. Primary completion date: Dec 1, 2024 to Jun 30, 2025v7 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 24 to 30
    • Study completion date: Mar 20, 2025 to Jul 15, 2025
    • Site details revised at 2 of 2 sites
  3. Start date: May 23, 2023 to Jun 1, 2023
    • Study sites revised (2)
    v6
  4. Primary completion date: Sep 20, 2024 to Dec 1, 2024
    • Study completion date: Dec 30, 2024 to Mar 20, 2025
    v5
  5. Interventions: Liraglutide or Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion… to Diethylpropion (Drug), Liraglutide (Drug), Naltrexone/Bupropion (Drug), Phentermine (Drug), Phentermine-Topiramate combination (Drug)…v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Feb 20, 2024 to Sep 20, 2024v3 Show 4 more changesShow less
    • Study sites: 1 to 2
    • Study completion date: Apr 30, 2024 to Dec 30, 2024
    • Interventions: Liraglutide or Semaglutide (Drug), Phentermine-Topiramate combination (Drug) to Liraglutide or Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion…
    • Collaborators: 2 to 3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Study sites: 2 to 1
    • Primary completion date: Dec 30, 2023 to Feb 20, 2024
    • Study completion date: Jan 15, 2024 to Apr 30, 2024
    • Start date changed from estimate of Mar 15, 2023 to May 23, 2023
    • Eligibility criteria shortened, about 16 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Trial Details
NCT Number NCT05756764
Lead Sponsor Louisiana State University Health Sciences Center in New Orleans
Collaborators: Tulane University, Pennington Biomedical Research Center, Ochsner Health System
Conditions
(from sponsor)		 Obesity
Related terms Dyslipidemias, Inflammation, Metabolic Syndrome, Obesity
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov